List of Nuzyra drug patents

Nuzyra is owned by Paratek Pharms Inc.

Nuzyra contains Omadacycline Tosylate.

Nuzyra has a total of 10 drug patents out of which 0 drug patents have expired.

Nuzyra was authorised for market use on 02 October, 2018.

Nuzyra is available in powder;intravenous dosage forms.

Nuzyra can be used as treatment of subjects having bacterial skin or skin structure infection, treatment of community acquired bacterial pneumonia, treatment of bacterial skin and skin structure infections, treatment of bacterial skin and skin structure infection.

Drug patent challenges can be filed against Nuzyra from October, 2027.

The generics of Nuzyra are possible to be released after 31 October, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2023

(4 months from now)

US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(7 months from now)

US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(6 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(6 years from now)

US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(6 years from now)

US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds
Mar, 2031

(8 years from now)

US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in